Press review

 - 

German online clinical trial portal Viomedo bought by Switzerland's Clariness

Country : Germany, U.S.

Keywords :
BERLIN, 9 Nov (APM) - Swiss company Clariness has bought German online clinical trials platform Viomedo, Handelsblatt reported on Wednesday (p45).
Viomedo, founded in 2015, is now the largest search engine for clinical trials in Germany, Handelsblatt said.
Clariness, specialised in patient recruitment, study feasibility and patient surveys, operates in 45 countries. The purchase price was not disclosed.

Biotech BioNTech cooperates with Penn university on mRNA vaccines

German biotech BioNTech has signed an agreement with the University of Pennsylvania for the development of mRNA-based vaccine for 10 infectious disease indications, reported Frankfurter Allgemeine Zeitung (FAZ) on Tuesday (p33).
The new cooperation opens up a huge network of U.S. researchers for BioNTech since the Penn team is leading the development of novel vaccine concepts for the prevention of infectious diseases, CEO Ugur Sahin said.

Last days for Stada shares

Shares of German generic drugmaker Stada are likely to be delisted before the end of November, FAZ said on Wednesday (p25).
Stada shareholders had until Thursday to sell the remainder of the stock to Bain Capital and Cinven, who took control of Stada in autumn 2017. They were offering €81.73 euros per share.
Bain and Cinven want to reduce reporting obligations and save costs with the end of the listing.

Promising Phase II results for GSK's tuberculosis vaccine candidate

GlaxoSmithKline's vaccine candidate M72/AS01 prevented 54% of tuberculosis outbreaks in infected patients, according to Phase II results published in the New England Journal of Medicine (NEJM), Sueddeutsche Zeitung (SZ) reported on Monday (p14).
Even a vaccine with an efficacy of 20% could be cost-effective, SZ wrote, as tuberculosis pathogens are often resistant to antibiotics and have made the disease the world's most deadly illness.

Israeli biotech develops HIV drug Gammora

Israeli biotech Zion Medical has published promising results for its HIV drug candidate Gammora, reports Die Welt on Friday (p20).
The drug has reduced HIV levels in eight patients by up to 99% in a two-phase, 10-week treatment including antiretrovirals. If confirmed in further trials, it might be a cure for the infection, chief developer Esmira Naftali told Die Welt.
Gammora first activates HIV, but in a way that causes the infected cells and their viruses to gradually die.
hm/so/clg

[HM8PHX2X9]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to our last stories

Request a trial to assess coverage that includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.